In conclusion, our work provides a rationale for the development of a Usp9x inhibitor (small molecule) for overcoming resistance to treatment by MAPK/ERK inhibitors via depletion of SOX2 in melanoma and other tumors including prostate. This evidence concerns the gene USP9X and melanoma.